CR7899A - Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa - Google Patents

Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa

Info

Publication number
CR7899A
CR7899A CR7899A CR7899A CR7899A CR 7899 A CR7899 A CR 7899A CR 7899 A CR7899 A CR 7899A CR 7899 A CR7899 A CR 7899A CR 7899 A CR7899 A CR 7899A
Authority
CR
Costa Rica
Prior art keywords
diazenpamdionilo
antienoplastic
inhibiting
effectiveness
derivatives
Prior art date
Application number
CR7899A
Other languages
English (en)
Inventor
Ninkovic Sacha
John Bennett Michael
Yuanjin Rui Eugene
Wang Fen
Pritchett Benedict Suzanne
Teng Min
Wang Yong
Zhu Jinjiang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR7899A publication Critical patent/CR7899A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Proteina quinasas, tales como CHK-1, que inhiben compuestos triciclicos de la siguiente formula (en la que R2, R3 y R4 son como se han definido en la memoria descriptiva) composiciones farmaceuticas que contienen cantidades eficaces de dichos compuestos o sus sales son utiles como un unico agente o en combinacion con un agente anti-neoplasico o radiacion que tienen un efecto antineoplasico para tratar enfermedades o afecciones tales como canceres.
CR7899A 2003-01-09 2005-07-08 Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa CR7899A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43939603P 2003-01-09 2003-01-09

Publications (1)

Publication Number Publication Date
CR7899A true CR7899A (es) 2005-08-05

Family

ID=32713475

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7899A CR7899A (es) 2003-01-09 2005-07-08 Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa

Country Status (35)

Country Link
US (3) US6967198B2 (es)
EP (2) EP1947102A1 (es)
JP (1) JP3990718B2 (es)
KR (1) KR100697746B1 (es)
CN (1) CN1759118B (es)
AP (1) AP2048A (es)
AT (1) ATE404564T1 (es)
AU (1) AU2004203977B2 (es)
BR (1) BRPI0406701A (es)
CA (1) CA2512683C (es)
CR (1) CR7899A (es)
CY (1) CY1108408T1 (es)
DE (1) DE602004015724D1 (es)
DK (1) DK1585749T3 (es)
EA (1) EA009337B1 (es)
EC (1) ECSP055911A (es)
ES (1) ES2309484T3 (es)
GE (1) GEP20084367B (es)
HK (1) HK1086257A1 (es)
HR (1) HRP20050624A2 (es)
IL (1) IL169082A (es)
IS (1) IS7884A (es)
MA (1) MA27703A1 (es)
MX (1) MXPA05007352A (es)
NO (1) NO20053775L (es)
NZ (1) NZ540638A (es)
OA (1) OA13017A (es)
PL (1) PL378372A1 (es)
PT (1) PT1585749E (es)
RS (1) RS20050522A (es)
SI (1) SI1585749T1 (es)
TN (1) TNSN05176A1 (es)
UA (1) UA80733C2 (es)
WO (1) WO2004063198A1 (es)
ZA (1) ZA200504674B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1467730A4 (en) * 2002-01-22 2010-03-10 Univ California Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof
EA009337B1 (ru) * 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии
JP2008530575A (ja) * 2005-02-18 2008-08-07 アストラゼネカ アクチボラグ Ｃｈｋ１阻害薬に対する応答性を判定する方法
KR100912998B1 (ko) 2005-03-29 2009-08-20 이코스 코포레이션 Ｃｈｋ1 억제에 유용한 헤테로아릴 우레아 유도체
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
NZ565378A (en) 2005-06-29 2011-03-31 Threshold Pharmaceuticals Inc Phosphoramidate alkylator prodrugs
WO2007022273A2 (en) 2005-08-15 2007-02-22 The Regents Of The University Of California Vegf-activated fas ligands
US8143052B2 (en) 2005-08-25 2012-03-27 Ube Industries, Ltd. Process for preparing optically active (S or R)-α amino acid and (R or S)-α amino acid ester in one phase organic reaction medium
US7645885B2 (en) * 2005-08-26 2010-01-12 The Regents Of The University Of California Non-steroidal antiandrogens
EP2004655A1 (en) * 2006-04-04 2008-12-24 Pfizer Products Incorporated Polymorphic forms of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4 l)-1-oxo-2,6-dihydro-1h-ý1,2¨diazepinoý4,5,6-cd¨indol-8-yl)acetamide
WO2007113671A1 (en) * 2006-04-04 2007-10-11 Pfizer Products Inc. Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
JP2010510222A (ja) * 2006-11-17 2010-04-02 シェーリング コーポレイション 増殖性障害に対する併用療法
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
ES2378513T3 (es) * 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
EP2346881A1 (en) * 2008-10-10 2011-07-27 Priaxon AG Novel compounds which modulate kinase activity
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
BR112013028665A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
US9254299B2 (en) 2011-12-22 2016-02-09 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer
DK2797921T3 (en) * 2011-12-31 2017-10-02 Beigene Ltd FUSED TETRA- OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARB INHIBITORS
EA027241B1 (ru) 2011-12-31 2017-07-31 Бейджен, Лтд. Конденсированные тетра- или пентациклические пиридофталазиноны в качестве ингибиторов parp
CN102746211B (zh) * 2012-06-27 2015-05-27 上海泰坦化学有限公司 一种取代吲哚-3-甲醛类化合物的制备方法
TWI633107B (zh) * 2013-05-22 2018-08-21 開曼群島商百濟神州生物科技有限公司 作為ｐａｒｐ抑制劑的稠合四或五環二氫二氮呯并咔唑酮
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
CA2950780C (en) 2014-06-17 2023-05-16 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of chk1 and atr inhibitors
US10457680B2 (en) * 2015-08-25 2019-10-29 Beigene, Ltd. Process for preparing a PARP inhibitor, crystalline forms, and uses thereof
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
EP3519051B1 (en) 2016-09-27 2021-09-22 Beigene, Ltd. Treatment of cancers using combination comprising parp inhibitors
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Ｐａｒｐ阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
US10899763B2 (en) 2017-02-28 2021-01-26 Beigene, Ltd. Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereof
US11661581B2 (en) * 2017-05-25 2023-05-30 University Of Massachusetts Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
RU2764243C2 (ru) * 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
WO2020154608A1 (en) * 2019-01-25 2020-07-30 Numedii, Inc. Method for treating idiopathic pulmonary fibrosis
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
WO2021104461A1 (zh) 2019-11-29 2021-06-03 南京明德新药研发有限公司 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
WO2022011458A1 (en) * 2020-07-13 2022-01-20 Ontario Institute For Cancer Research (Oicr) Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
CN115698019A (zh) * 2020-07-31 2023-02-03 正大天晴药业集团股份有限公司 用作parp抑制剂的吲哚并七元酰肟类似物的结晶及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9722320D0 (en) 1997-10-22 1997-12-17 Janssen Pharmaceutica Nv Human cell cycle checkpoint proteins
US6383744B1 (en) 1998-07-10 2002-05-07 Incyte Genomics, Inc. Human checkpoint kinase
WO2000016781A1 (en) 1998-09-18 2000-03-30 Smithkline Beecham Corporation Chk1 kinase inhibitors
PT1140936E (pt) * 1999-01-11 2004-06-30 Agouron Pharma Inibidores triciclicos de poli(adp-ribose) polimerases
ES2302699T3 (es) 1999-08-27 2008-08-01 Novartis Vaccines And Diagnostics, Inc. Oligonucleotidos quimericos antisentido y formulaciones de transfeccion celular de los mismos.
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
US6670167B1 (en) 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
DE60019318T2 (de) 1999-09-22 2006-03-09 Canbas Co., Ltd., Numazu Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
US6211164B1 (en) 2000-03-10 2001-04-03 Abbott Laboratories Antisense oligonucleotides of the human chk1 gene and uses thereof
AU3652102A (en) * 2000-12-01 2002-06-11 Guilford Pharm Inc Compounds and their uses
UA76977C2 (en) 2001-03-02 2006-10-16 Icos Corp Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
EA009337B1 (ru) * 2003-01-09 2007-12-28 Пфайзер Инк. Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии

Also Published As

Publication number Publication date
MA27703A1 (fr) 2006-01-02
CA2512683C (en) 2010-03-16
EP1585749B1 (en) 2008-08-13
HRP20050624A2 (en) 2006-02-28
ECSP055911A (es) 2005-11-22
DE602004015724D1 (de) 2008-09-25
US7462713B2 (en) 2008-12-09
EA009337B1 (ru) 2007-12-28
ZA200504674B (en) 2006-07-26
NO20053775L (no) 2005-09-16
AP2005003353A0 (en) 2005-09-30
KR20050092397A (ko) 2005-09-21
DK1585749T3 (da) 2008-09-22
EP1585749A1 (en) 2005-10-19
SI1585749T1 (sl) 2008-10-31
AU2004203977B2 (en) 2010-06-17
EP1947102A1 (en) 2008-07-23
US7132533B2 (en) 2006-11-07
CY1108408T1 (el) 2014-02-12
NO20053775D0 (no) 2005-08-08
UA80733C2 (en) 2007-10-25
JP3990718B2 (ja) 2007-10-17
ES2309484T3 (es) 2008-12-16
US6967198B2 (en) 2005-11-22
GEP20084367B (en) 2008-05-13
AU2004203977A1 (en) 2004-07-29
MXPA05007352A (es) 2006-02-17
CA2512683A1 (en) 2004-07-29
IS7884A (is) 2005-06-09
RS20050522A (en) 2007-12-31
CN1759118A (zh) 2006-04-12
CN1759118B (zh) 2010-12-08
EA200500893A1 (ru) 2006-02-24
ATE404564T1 (de) 2008-08-15
IL169082A (en) 2011-02-28
WO2004063198A1 (en) 2004-07-29
US20060004052A1 (en) 2006-01-05
BRPI0406701A (pt) 2005-12-20
US20050075499A1 (en) 2005-04-07
AP2048A (en) 2009-09-24
OA13017A (en) 2006-11-10
KR100697746B1 (ko) 2007-03-22
HK1086257A1 (en) 2006-09-15
PT1585749E (pt) 2008-10-23
PL378372A1 (pl) 2006-04-03
NZ540638A (en) 2007-12-21
US20070135415A1 (en) 2007-06-14
JP2006516274A (ja) 2006-06-29
TNSN05176A1 (fr) 2007-06-11

Similar Documents

Publication Publication Date Title
CR7899A (es) Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
CR20110016A (es) Compuestos quimicos 251
BR112018004175B8 (pt) Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
BRPI0511967A (pt) usos de derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina e compostos relacionados para o tratamento de cáncer, suas composições farmacêuticas, embalagens comerciais e respectivo kit
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
ECSP055582A (es) Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
DOP2004000949A (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos
ECSP109953A (es) Derivados de piridazinona
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
SV2009003335A (es) Formulaciones para el cancer
PA8719401A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
ECSP099767A (es) Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
AR063819A1 (es) Pirrolo[1,2-a]imidazoldiona eficaz en el tratamiento de neurotoxicidad periferica inducida por agentes quimioterapeuticos. composiciones farmaceuticas y usos.
NI200700323A (es) 4-anilino-3-quinolinocarbonitrilo para el tratamiento de cáncer
CU23421A3 (es) Derivados de diazepinoindol como inhibidores de quinasa
HN2004000224A (es) Derivados de 2 - aminobenzoilo
UY27132A1 (es) Naftostirilos
CU20100265A7 (es) Compuestos químicos 251